<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04541719</url>
  </required_header>
  <id_info>
    <org_study_id>MFM-XYZ-2017</org_study_id>
    <nct_id>NCT04541719</nct_id>
  </id_info>
  <brief_title>Patient Controlled Remifentanil Analgesia for Normal Labour</brief_title>
  <official_title>Patient Controlled Remifentanil Analgesia vs. Epidural Analgesia for Normal Labour. A Prospective Randomised Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient controlled remifentanil analgesia might offer comparative overall patient&#xD;
      satisfaction and improved quality of analgesia after normal labour with continuous epidural&#xD;
      analgesia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We are aiming to study the effects of patient controlled remifentanil analgesia and epidural&#xD;
      analgesia for normal labour in full term parturients on:&#xD;
&#xD;
        -  Peripartum analgesia&#xD;
&#xD;
        -  Overall patient's satisfaction&#xD;
&#xD;
        -  Maternal adverse effects&#xD;
&#xD;
        -  Neonatal outcomes&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no participants enrolled&#xD;
  </why_stopped>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Actual">July 1, 2018</completion_date>
  <primary_completion_date type="Actual">May 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall patient's satisfaction</measure>
    <time_frame>For 24 hours after labour</time_frame>
    <description>As being assesses using 100-mm visual analog score (0: unsatisfied, 100: very satisfied)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Visual Analog Score at rest</measure>
    <time_frame>For 24 hours after the start of labour pain</time_frame>
    <description>As being assesses using 10-cm visual analog score (0: no pain, 10: very agonising pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Visual Analog Score on movement</measure>
    <time_frame>For 24 hours after the start of labour pain</time_frame>
    <description>As being assesses using 10-cm visual analog score (0: no pain, 10: very agonising pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal nausea and vomiting</measure>
    <time_frame>For 24 hours after the start of labour pain</time_frame>
    <description>(0: no nausea or vomiting, 1: severe nausea, 3: vomiting)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal respiratory depression</measure>
    <time_frame>For 24 hours after the start of labour pain</time_frame>
    <description>If respiratory rate decreases less than 10/min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Apgar score at 1 min</measure>
    <time_frame>For 5 min after birth</time_frame>
    <description>Assessed using 5-points Apgar score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal Apgar score at 5 min</measure>
    <time_frame>For 5 min after birth</time_frame>
    <description>Assessed using 5-points Apgar score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal blood PaO2</measure>
    <time_frame>For 5 min after birth</time_frame>
    <description>PaO2 value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal blood PaCO2</measure>
    <time_frame>For 5 min after birth</time_frame>
    <description>PaCO2 value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal blood pH</measure>
    <time_frame>For 5 min after birth</time_frame>
    <description>pH value</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Labor Pain</condition>
  <condition>Full Term Pregnancy</condition>
  <arm_group>
    <arm_group_label>Patient-controlled remifentanil analgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will received Patient-controlled remifentanil analgesia starting from labour pain until delivery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Epidural analgesia</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will received continuous epidural analgesia starting from labour pain until delivery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patient-controlled remifentanil analgesia</intervention_name>
    <description>Patient controlled remifentanil analgesia with a regimen to provide a bolus of 40 Î¼g remifentanil with a lockout interval of 2 min</description>
    <arm_group_label>Patient-controlled remifentanil analgesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epidural analgesia</intervention_name>
    <description>Patients will receive continuous epidural analgesia using bupivacaine 0.125% in conjunction with fentanyl 2 ug/ml at a rate of 8-15 ml/hr</description>
    <arm_group_label>Epidural analgesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age &gt; 36 weeks&#xD;
&#xD;
          -  American Society of Anesthesiologists physical class I to III&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to study solution&#xD;
&#xD;
          -  Contraindications to epidural analgesia&#xD;
&#xD;
          -  Non consented parturients&#xD;
&#xD;
          -  Communications barriers.&#xD;
&#xD;
          -  Intrauterine foetal growth retardation&#xD;
&#xD;
          -  Foetal distress&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nabil A Abd El Raouf, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Professor in Cardiothoracic Ananesthesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mansoura University Hospitals</name>
      <address>
        <city>Mansoura</city>
        <state>DK</state>
        <zip>050</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 2, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>Mohamed R El Tahan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Labor Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

